Dyne Therapeutics, Inc. — Biotechnology. Scored on the same transparent model behind the daily rankings.
★
DYN
Dyne Therapeutics, Inc. · Biotechnology
FCF-$480mF
Rev——
D/E0.33B
P/S——
PEG——
9.8Score
$26.09$4.9B
1Y Target$39.40Analyst consensus · 15 analysts
5Y Target$68.91Compound horizon
10Y Target$123.16Long-dated conviction
FCF-$480mTTMF
FCF is negative (-$480m) — cash-burning phase; acceptable only for pre-profit spec names
Rev——
Revenue growth data unavailable or not applicable — neutral default
D/E0.33B
D/E 0.33 — near the Healthcare debt median (≈60th pctile)
P/S——
P/S unavailable
PEG——
PEG not meaningful — earnings growth negative or data unavailable
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 9.8
Quality17.5
Growth10.0
Value5.4
Why this score
Diluting shareholders
Entry · Margin of safety
52-week rangeNear 52-week high
4% off the 12-month high
Quality signals · context only
ROIC-59.6% · Freturn on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Dyne’s FORCE platform positions it to be the first-mover in delivering disease‑modifying therapeutics for myotonic dystrophy type 1 and Duchenne muscular dystrophy, unlocking a multibillion‑dollar neuromuscular market. The market cap of $4.9b and a low debt‑to‑equity of 0.33 give the company ample runway to fund late‑stage trials, while the consensus 12‑month price objective of $39.40 already reflects a >50% upside on the $26.09 share price. The thesis rests on the platform’s ability to compound as each program clears pivotal milestones, delivering successive revenue spikes.
Moat
The FORCE platform is a proprietary, modular delivery system that can be adapted across multiple rare muscle disorders, creating high switching costs for patients and physicians who have invested in the specific dosing and administration protocols. This IP‑protected technology, combined with Dyne’s exclusive focus on the U.S. neuromuscular pipeline, prevents easy replication by larger biotech rivals lacking a dedicated muscle‑disease engine.
Risk
Dyne still burns cash, generating a negative free cash flow of $480m over the trailing twelve months, and its profit margin is currently zero, meaning any delay in trial readouts could force additional financing that would dilute shareholders—a key signal flagged by our model. A missed pivotal endpoint in its Duchenne or Myotonic dystrophy programs would trigger a sharp sell‑off, confirming the bear case that the current valuation is unsustainable without near‑term data wins.
Horizon
1-3 yr $39.40 (15-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $68.91 — requires the platform / technology to reach commercial scale. 10 yr $123.16 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
DYN vs the Top Picks average
Pillar
DYN
Book avg
Diff
Quality
0.18
0.83
-0.66
Growth
0.10
0.87
-0.77
Value
0.05
0.76
-0.71
Averaged across the 30 names in today's Top Picks (mean score 81.6). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · DYN
Trend
+0.1 over 51 daily scores
From 9.7 (Jun 22) → 9.8 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
DYN at a glance
Every figure here comes from the same audited fundamentals behind the score. Charts drawn from data the score does not use say so on the card.
Position sizing · DYN
$
%
%
Shares to buy
76
Position size
$1,983
4.0% of portfolio
Stop price
$19.57
25% below $26.09
$ at risk if stopped
$495.71
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Dyne Therapeutics, Inc. (DYN): score, valuation & FAQ
Dyne Therapeutics, Inc. (DYN) is a Biotechnology company that scores 9.8 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
The model flags FCF (F) as weaker areas.
Is DYN a good stock to buy?
Bull Rankings scores DYN 9.8 out of 100 on its quality-growth model, which is a weak reading. A score is a quantitative screen of Dyne Therapeutics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does DYN score 9.8 on Bull Rankings?
The score leans on quality at 17.5 out of 100, with value the weakest pillar at 5.4 — the three combine geometrically, so a weak one cannot be papered over by a strong one. DYN grades middle-of-pack across the graded signals, and is held back by FCF (F). Each signal is graded against sector-aware thresholds rather than one absolute bar, so DYN is measured against Biotechnology peers, not against the market as a whole.
Is DYN overvalued or undervalued?
We don't compute a reliable discounted-cash-flow value for DYN — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.
What are the main risks of investing in DYN?
Dyne still burns cash, generating a negative free cash flow of $480m over the trailing twelve months, and its profit margin is currently zero, meaning any delay in trial readouts could force additional financing that would dilute shareholders—a key signal flagged by our model. A missed pivotal endpoint in its Duchenne or Myotonic dystrophy programs would trigger a sharp sell‑off, confirming the bear case that the current valuation is unsustainable without near‑term data wins.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.